BriaCell Therapeutics Corp. (BCTXW)

NASDAQ: BCTXW · Real-Time Price · USD · Warrants
0.0563
-0.0027 (-4.58%)
Nov 12, 2025, 4:00 PM EST - Market closed
-4.58%
Market Cap18.97M
Revenue (ttm)n/a
Net Income (ttm)-26.31M
Shares Out 1.88M
EPS (ttm)-62.19
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume90,639
Open0.0545
Previous Close0.0590
Day's Range0.0486 - 0.0581
52-Week Range0.0113 - 0.7000
Beta1.96
Analystsn/a
Price Targetn/a
Earnings Daten/a

About BCTXW

BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agreement with the University of Maryland, Baltimore Co... [Read more]

Industry Biotechnology
Sector Healthcare
CEO William Williams
Employees 16
Stock Exchange NASDAQ
Ticker Symbol BCTXW
Full Company Profile

News

There is no news available yet.